Evaluation of neurohumoral factors and water clearance for treating acute decompensated heart failure with salt

Evaluation of neurohumoral factors and water clearance for treating acute decompensated heart failure with salt - Enter-salt

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029129

Enrollment

Registered

2017-09-13

Start date

2017-09-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute decompensated heart failure

Interventions

Hypertonic saline group: continuous intravenous infusion of 120mL 2.4% hypertonin saline for 1 hour after bolus injection of 40mg furosemide. Glucose group: continuous intravenous infusion of 120mL 5

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with age 20 and over. 2. Patients who are hospitalized due to acute decompensated heart failure 3. Patients who gave written informed consent

Exclusion criteria

Exclusion criteria: 1. Patients with less than 90mmHg of systolic blood pressure 2. Patients with acute coronary sydrome 3. Patients requiring intra-aortic balloon pump therapy and extracorporeal circulation system 4. Patients with severe kidney disease(less than 15ml/min/1.73m2 of eGFR) 5. Patients with regular hemodialysis 6. Patients with more than 148mEq/L of serum sodium level 7. Patients with endocrine disease (eg: SIADH and aldosteronism) 8. Patients who already participate in other clinical trials or plan to participate during this study 9. For other reasons, patients whom the investigators deem inappropriate to participate in this study

Design outcomes

Primary

Measure	Time frame
1. Change in serum anti-diuretic hormone during 24 hours 2. Change in urine clearance during 24 hours	—

Secondary

Measure	Time frame
1. Change in serum osmolality during 24 hours 2. Change in urinary osmolality during 24 hours 3. Change in urinary volume during 24 hours 4. Change in systolic blood pressure during 24 hours 5. Change in diastolic blood pressure during 24 hours 6. Change in heart rate during 24 hours 7. Change in serum sodium level during 24 hours 8. Change in serum potassium during 24 hours 9. Change in serum chloride during 24 hours 10. Change in urinary sodium level during 24 hours 11. Change in urinary potassium during 24 hours 12. Change in urinary chloride during 24 hours 13. Change in plasma aldosterone concentration during 24 hours 14. Change in plasma renin activity during 24 hours 15. Change in plasma catecholamine during 24 hours 16. Change in blood urea nitrogen during 24 hours 17. Change in urinary urea nitrogen during 24 hours 18. Change in serum creatinine during 24 hours	—

Measure

Time frame

1. Change in serum osmolality during 24 hours 2. Change in urinary osmolality during 24 hours 3. Change in urinary volume during 24 hours 4. Change in systolic blood pressure during 24 hours 5. Change in diastolic blood pressure during 24 hours 6. Change in heart rate during 24 hours 7. Change in serum sodium level during 24 hours 8. Change in serum potassium during 24 hours 9. Change in serum chloride during 24 hours 10. Change in urinary sodium level during 24 hours 11. Change in urinary potassium during 24 hours 12. Change in urinary chloride during 24 hours 13. Change in plasma aldosterone concentration during 24 hours 14. Change in plasma renin activity during 24 hours 15. Change in plasma catecholamine during 24 hours 16. Change in blood urea nitrogen during 24 hours 17. Change in urinary urea nitrogen during 24 hours 18. Change in serum creatinine during 24 hours

—

Countries

Japan

Contacts

Public ContactYoshitaka Okuhara

Hyogo College of Medicine Department of Internal Medicine, Cardiovascular Division, Hyogo College of Medicine

okuhara@hyo-med.ac.jp0798-45-6553

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026